Introduction：Basic information about CAS 129731-10-8|Vorozole, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Vorozole |
|---|
| CAS Number | 129731-10-8 | Molecular Weight | 324.77 |
|---|
| Density | 1.44g/cm3 | Boiling Point | 575.1ºC at 760 mmHg |
|---|
| Molecular Formula | C16H13ClN6 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 301.6ºC |
|---|
Names
| Name | 6-[(S)-(4-chlorophenyl)-(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole |
|---|
| Synonym | More Synonyms |
|---|
Vorozole BiologicalActivity
| Description | Vorozole is a potent and selective, orally active non-steroidal aromatase inhibitor[1][2]. Vorozole shows antitumor activity in vivo. Vorozole has the potential for the research of mammary cancer[3]. |
|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Others >>Aromatase |
|---|
| In Vitro | Vorozole inhibits aromatase activity with an IC50s of 1.4 nM in FSH-stimulated rat granulosa cells[4]. |
|---|
| In Vivo | Vorozole (0.8-1.25 mg/kg; Gavage; daily for 77 dayss) shows antitumor effect and increase the release of serum insulin-like growth factor (IGF)-1 and serum testosterone levels[3]. Vorozole (p.o.; 5 days) dose-dependently reduced uterus weight and completely inhibited tumor aromatase in ovariectomized nude mice[4]. Animal Model: Female Sprague-Dawley rats[3] Dosage: 0.08, 0.16, 0.31, 0.63 or 1.25 mg/kg Administration: Gavage; daily (starting at 43 days of age) for 77 days; given a single i.v. dose of methylnitrosourea (MNU) (50 mg/kg body wt) after 7 days Result: Caused a dose-dependent increase in body weight gain and decrease in cancer incidence, increased the insulin-like growth factor (IGF)-1, serum testosterone levels. |
|---|
| References | [1]. Wouters W, et al. Pharmacology of vorozole. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):617-21. [2]. Wiseman LR, et al. Vorozole. Drugs Aging. 1997 Sep;11(3):245-50; discussion 251-2. [3]. Lubet RA,et al. Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis. 1998 Aug;19(8):1345-51. [4]. Wouters W, et al. Pharmacology of vorozole. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):617-21. |
|---|
Chemical & Physical Properties
| Density | 1.44g/cm3 |
|---|
| Boiling Point | 575.1ºC at 760 mmHg |
|---|
| Molecular Formula | C16H13ClN6 |
|---|
| Molecular Weight | 324.77 |
|---|
| Flash Point | 301.6ºC |
|---|
| Exact Mass | 324.08900 |
|---|
| PSA | 61.42000 |
|---|
| LogP | 2.85090 |
|---|
| Vapour Pressure | 3.15E-13mmHg at 25°C |
|---|
| Index of Refraction | 1.738 |
|---|
| InChIKey | XLMPPFTZALNBFS-INIZCTEOSA-N |
|---|
| SMILES | Cn1nnc2ccc(C(c3ccc(Cl)cc3)n3cncn3)cc21 |
|---|
Safety Information
Customs
| HS Code | 2933990090 |
|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|---|
Synonyms
| Vorozolum |
| 6-[(S)-(4-Chlorophenyl)(1H-1,2,4-triazol-1-yl)methyl]-1-methyl-1H-benzotriazole |
| (S)-6-[(4-Chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl]-1-methyl-1H-benzotriazole |
| Vorozolum [INN-Latin] |
| (+)-(S)-6-(p-Chloro-α-1H-1,2,4-triazol-1-ylbenzyl)-1-methyl-1H-benzotriazole |
| Rivizor |
| 1H-1,2,3-Benzotriazole, 6-[(S)-(4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl]-1-methyl- |
| (+)-(S)-6-[4-Chloro-a-(1H-1,2,4-triazol-1-yl)benzyl]-1-methyl-1H-benzotriazole |
| Vorozole |
| Rivizor (TN) |
| Vorozol [INN-Spanish] |
| Vorozol |
| 1H-Benzotriazole, 6-((4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl)-1-methyl-, (S)- |
